Feel Healthy Today
  • Home
  • Recipes
  • Health News
  • Fitness News
  • Weight Loss
  • Contact
  • Subscribe

Health News

Houston Health Department launches new COVID-19 mental health support program - KPRC Click2Houston

10/1/2020

0 Comments

 
Houston Health Department launches new COVID-19 mental health support program - KPRC Click2Houston

https://ift.tt/34eQbVX

HOUSTON – Mayor Sylvester Turner, U.S. Congresswoman Sheila Jackson Lee, and the Houston Health Department are working together to launch a new effort to support mental health during the coronavirus pandemic.

The program, called “Let’s Beat COVID-19: Health Education and Support Services,” includes a mental health helpline and other resources to help people adjust to the pandemic mentally and emotionally, according to the City of Houston in a release.

Stephen L. Williams, director of the Houston Health Department said these services will be available to anyone, however, they will also focus on parents and guardians of school-aged children, childcare providers, teachers, and City of Houston staff on the frontlines.

The mental health program will also offer virtual support groups, toolkits and trainings to support mental and emotional needs, the department said.

The helpline launches Oct.1 and will be open seven days a week from 1 p.m. to 11 p.m. through Dec. 24. Houstonians can call 713-999-9442 to reach a mental health professional for appropriate intervention.

Copyright 2020 by KPRC Click2Houston - All rights reserved.





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

First COVID-19 death at DeKalb's Oak Crest Retirement Center; 16 new local cases Wednesday - DeKalb Daily Chronicle

10/1/2020

0 Comments

 
First COVID-19 death at DeKalb's Oak Crest Retirement Center; 16 new local cases Wednesday - DeKalb Daily Chronicle

https://ift.tt/2Sejv9G

As a public service, Shaw Media will provide open access to information related to the COVID-19 (Coronavirus) emergency. Sign up for the newsletter here

Another DeKalb County resident died due to complications from the novel coronavirus, according to the DeKalb County Health Department, which on Wednesday reported 16 new cases and the first death in a resident of Oak Crest-DeKalb Area Retirement Center.

Total cases in the county rose to 1,682 and the death toll rose to 39 after the death of a man in his 90s who lived at Oak Crest. Willow Crest Nursing Pavilion in Sandwich also reported its 67th case, the 26th in a staff member. DeKalb County Rehabilitation and Nursing Center remained at eight cases, Oak Crest remained at nine and Prairie Crossing Living and Rehabilitation Center in Shabbona, which reported its first cases Tuesday, remained at three.

Region 1, which includes DeKalb, Sauk Valley and Rockford, officially passed the threshold for mitigations Wednesday, recording a third straight day with a seven-day rolling positivity average of over 8%, hitting 8.4%.

According to the Illinois Public Health Department's daily county testing data, which is on a three-day lag, DeKalb County had a daily positivity rate of 4.2% on Sunday, down from 12.2% the day before. The rolling positivity rate dropped to 6.9%.

New cases included three in patients under 20, two in their 20s, three in their 30s, four in their 40s, one in their 50s, two in their 70s and one in their 80s.

In total, 283 cases have been reported among residents younger than 20, 510 in their 20s, 224 in their 30s, 214 in their 40s, 177 in their 50s, 109 in their 60s, 77 in their 70s and 88 in their 80s or older.

According to county data, the city of DeKalb reports between 886 and 890 cases. There are between 216 and 220 cases in Sycamore; 171 and 175 in Sandwich; 126 and 130 cases in Genoa; 76 and 80 cases in Cortland; 31 and 35 in Hinckley; 26 and 30 in Kingston and Kirkland; 21 and 25 cases in Malta and Somonauk; and 11 and 15 in Waterman, Maple Park and Shabbona. Esmond, Leland and Earlville each report between one and five cases.

Cases listed on the county site are for those only occurring within the county; for instance, the Maple Park numbers only count residents who reside in DeKalb County.

The IDPH lists cases and tests performed by ZIP code, while the county health department lists cases by municipality. Numbers vary between state and health departments because of data lags.

The 60115 ZIP code, including DeKalb, had 843 cases reported and 14,693 tests administered (a positivity rate of 5.7%); the 60178 ZIP code, including Sycamore, had 223 cases and 5,734 tests (3.9%); the 60548 ZIP code, including Sandwich, had 4,066 tests and 248 cases (6.1%); the 60112 ZIP code, including Cortland, had 79 cases and 1,294 tests (6.1%); the 60135 ZIP code, including Genoa, had 121 cases and 1,942 tests (6.2%); the 60145 ZIP code, including Kingston, had 27 cases and 488 tests (5.5%); the 60146 ZIP code, including Kirkland, had 35 cases and 697 tests (5.0%); the 60520 ZIP code, including Hinckley, had 31 cases and 696 tests (4.6%); the 60550 ZIP code, including Shabbona, had 15 cases and 601 tests (2.5%); the 60151 ZIP code, including parts of Maple Park in both DeKalb and Kane counties, had 45 cases and 981 tests (4.6%); and the 60556 ZIP code, including Waterman, had 13 cases and 415 tests (3.1%).

The IDPH reported 293,274 people in Illinois have tested positive for COVID-19, while 8,672 people have died statewide. The number of tests performed rose to 5,624,822. The site also lists statewide recovery rates, calculated by recovered cases divided by the sum of recovered cases and dead cases. The statewide recovery rate remained at 96%.

The county released its weekly testing and recovery data on Friday, with 1,078 total recovered since the pandemic began locally. A total of 33,814 tests have been conducted on residents.





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

Delirium a key sign of COVID-19 in frail older people - Science Daily

10/1/2020

0 Comments

 
Delirium a key sign of COVID-19 in frail, older people - Science Daily

https://ift.tt/3l23bVI

A new analysis of data from researchers at King's College London using information from the COVID Symptom Study app and patients admitted to St Thomas' Hospital in London, has shown that delirium -- a state of acute confusion associated with a higher risk of serious illness and death -- is a key symptom of COVID-19 in frail, older people.

The findings, published in the journal Age and Ageing, highlight that doctors and carers should be aware of delirium as a possible early warning sign of COVID-19 in the elderly, even in the absence of more typical symptoms such as cough or fever.

Led by clinical fellow and geriatrician Dr Rose Penfold at King's College London, the researchers analysed data from two groups of older people aged 65 or over from March through May. The first group included 322 patients admitted to hospital with COVID-19 who had tested positive for COVID-19, while the second comprised 535 users of the COVID Symptom Study app who reported having had a positive test result.

They found that older adults admitted to hospital who were classified as frail according to a standard scale were more likely to have had delirium as one of their symptoms than people of the same age who were not classed as frail. Delirium, along with tiredness and breathlessness, were also more common in frailer users of the COVID Symptom Study app with COVID-19, compared with fitter people of the same age.

A third of app users experiencing delirium did not report suffering the 'classic' COVID-19 symptoms of cough and fever, while delirium was the only symptom for around one in five (18.9%) of hospitalised patients.

Frailty in the group of hospitalised patients was measured using the Clinical Frailty Scale (CFS) test, which is administered by a doctor. COVID Symptom Study App users were asked to complete a short questionnaire asking about their health, which is comparable to the CFS.

This is the first study showing that delirium is a likely symptom of COVID-19 in frail older adults, although the precise biological connection between the two conditions still needs to be understood. The findings also highlight the need for systematic assessment of frailty for older people, along with awareness and screening for delirium for this vulnerable population in hospitals, care homes and the community.

Dr Rose Penfold from King's College London said: "Older, frailer people are at greater risk from COVID-19 than those who are fitter, and our results show that delirium is a key symptom in this group. Doctors and carers should watch out for any changes in mental state in elderly people, such as confusion or strange behaviour, and be alert to the fact that this could be an early sign of coronavirus infection."

Dr Claire Steves from King's College London said: "The past six months have shown us that COVID-19 can spread catastrophically through care homes. Knowing that delirium is a symptom in frail, elderly people will help families and carers spot the signs earlier of COVID-19 and act appropriately and put in place infection control measures such as isolation, increased hygiene and personal protective equipment to protect this highly vulnerable group."

Professor Tim Spector, Professor of Genetic Epidemiology at King's College London and COVID Symptom Study lead, said: "In April we upgraded the COVID Symptom Study app to allow users to log health reports on behalf of friends and family who aren't able to access the app. This significantly increased the number of older people in the study, providing vital insights. We're hugely grateful to all our users and urge everyone to download the app and log their health and that of their loved ones on a daily basis as we move towards the winter months."

Story Source:

Materials provided by King's College London. Note: Content may be edited for style and length.





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

Governor Cuomo Updates New Yorkers on State's Progress During COVID-19 Pandemic - ny.gov

10/1/2020

0 Comments

 
Governor Cuomo Updates New Yorkers on State's Progress During COVID-19 Pandemic - ny.gov

https://ift.tt/34cKM1V

Governor Andrew M. Cuomo today updated New Yorkers on the state's progress during the ongoing COVID-19 pandemic. The number of new cases, percentage of tests that were positive and many other helpful data points are always available at forward.ny.gov.

 

"We're dealing with the cluster situation. We've had clusters in the past stemming from factories, churches, bars and other locations. Remember we started with New Rochelle, the first hotspot in the United States, which stemmed from someone who attended a religious gathering and then a wedding. And that was the first super spreader event, so we're quite familiar with this, and when there's a cluster, we are very aggressive on it and we're oversampling in the clusters," Governor Cuomo said. "We've deployed rapid testing machines. So you have two infection rates that you want to pay attention to: the statewide numbers and then the cluster numbers. All of this is a stark reminder that we need to stay smart and vigilant - wear a mask, socially distance, follow the public health guidance - because this thing is not over."

 

New York State continues to track clusters with a particular focus on the top 20 ZIP codes in which there have been hotspots. Within the 20 hotspot ZIP codes, the average rate of positive tests is 5.5 percent. The rate of positive tests for the remainder of New York State, not counting the top 20 ZIP codes, is 0.82 percent. The rate of positive tests for all of New York State, including the top 20 ZIP codes, is 1.02 percent. These 20 ZIP codes contained 23 percent of all positive cases in New York State yesterday, but represent only 6 percent of the state's population.

 

The Governor noted that 20 hotspot ZIP codes reported an average 5.5 percent positivity rate. Areas that had high positivity rates will be subject of focused testing efforts including access to rapid testing machines. These ZIP codes include:

 

REGION

COUNTY

ZIP

% POSITIVE

TESTS

POSITIVES

Mid-Hudson

Rockland

10952

17%

200

34

Mid-Hudson

Rockland

10977

14%

350

50

NYC

Kings

11230

8%

342

29

NYC

Kings

11204

6%

223

13

NYC

Kings

11219

5%

260

12

NYC

Kings

11223

4%

253

11

NYC

Kings

11229

4%

286

11

NYC

Kings

11210

4%

182

7

NYC

Kings

11234

4%

279

10

NYC

Bronx

10465

4%

140

5

NYC

New York

10040

4%

198

7

Mid-Hudson

Orange

10950

3%

86

3

NYC

Queens

11374

3%

151

5

NYC

Richmond

10306

3%

152

5

NYC

Richmond

10304

3%

185

6

Long Island

Suffolk

11717

3%

125

4

Long Island

Nassau

11580

3%

138

4

NYC

Queens

11691

3%

255

7

Long Island

Suffolk

11746

3%

183

5

NYC

Bronx

10462

3%

266

7

 

The Governor also announced the New York State Department of Financial Services will extend an emergency regulation requiring New York health insurers to waive out-of-pocket costs, including cost-sharing, deductibles, copayments and coinsurance, for in-network mental health services for New York's frontline essential workers during COVID-19 until November 27. The extension of this emergency regulation helps to ensure that cost-sharing is not a barrier to in-network mental health services during COVID-19 for health care workers, first responders, transit workers, food services workers, retail workers at essential businesses, and other frontline essential employees, who are required to directly interact with the public while working during this continuing public health emergency. Governor Cuomo first announced the State's directive requiring New York insurers to waive out-of-pocket costs for in-network mental health services for frontline essential workers during COVID-19 in May.

 

Yesterday, the State Liquor Authority and State Police Task Force visited 1,114 establishments in New York City and Long Island and observed 4 establishments that were not in compliance with state requirements. A county breakdown of yesterday's observed violations is below:

 

 

Today's data is summarized briefly below:

 

  • Patient Hospitalization - 605 (+34)
  • Patients Newly Admitted - 100
  • Hospital Counties - 38
  • Number ICU - 144 (-3)
  • Number ICU with Intubation - 67 (+6)
  • Total Discharges - 76,754 (+63)
  • Deaths - 9
  • Total Deaths - 25,479

 

Of the 97,960 test results reported to New York State yesterday, 1,000, or 1.02 percent, were positive. Each region's percentage of positive test results reported over the last three days is as follows:

 

REGION

SUNDAY

MONDAY

TUESDAY

Capital Region

0.9%

0.9%

0.5%

Central New York

0.8%

1.7%

0.4%

Finger Lakes

0.6%

0.9%

0.3%

Long Island

1.2%

1.2%

1.3%

Mid-Hudson

3.1%

2.0%

2.4%

Mohawk Valley

1.2%

0.8%

0.3%

New York City

1.6%

1.3%

1.2%

North Country

0.4%

0.2%

0.2%

Southern Tier

3.6%

1.9%

0.6%

Western New York

0.9%

1.3%

1.1%

 

Each New York City borough's percentage of positive test results reported over the last three days is as follows:

 

BOROUGH

SUNDAY

MONDAY

TUESDAY

Bronx

1.0%

1.0%

1.1%

Brooklyn

2.6%

1.7%

1.8%

Manhattan

0.8%

0.7%

0.6%

Queens

1.6%

1.5%

1.2%

Staten Island

1.3%

1.6%

2.2%

 

The Governor also confirmed 1,000 additional cases of novel coronavirus, bringing the statewide total to 458,649 confirmed cases in New York State. Of the 458,649 total individuals who tested positive for the virus, the geographic breakdown is as follows:

 

County

Total Positive

New Positive

Albany

3,120

4

Allegany

114

6

Broome

1,673

31

Cattaraugus

276

5

Cayuga

220

1

Chautauqua

590

5

Chemung

510

18

Chenango

253

2

Clinton

162

0

Columbia

595

3

Cortland

184

3

Delaware

136

0

Dutchess

5,137

7

Erie

11,500

55

Essex

169

1

Franklin

66

0

Fulton

339

0

Genesee

330

3

Greene

325

2

Hamilton

15

0

Herkimer

338

1

Jefferson

172

2

Lewis

50

0

Livingston

208

1

Madison

497

0

Monroe

6,085

11

Montgomery

235

1

Nassau

46,857

66

Niagara

1,788

5

NYC

244,041

446

Oneida

2,436

4

Onondaga

4,424

15

Ontario

475

0

Orange

12,143

21

Orleans

336

1

Oswego

503

4

Otsego

341

1

Putnam

1,617

5

Rensselaer

919

3

Rockland

15,452

110

Saratoga

1,066

6

Schenectady

1,410

5

Schoharie

85

0

Schuyler

43

0

Seneca

107

0

St. Lawrence

327

2

Steuben

453

3

Suffolk

46,517

53

Sullivan

1,604

4

Tioga

249

7

Tompkins

421

4

Ulster

2,280

8

Warren

391

5

Washington

302

1

Wayne

323

2

Westchester

38,239

57

Wyoming

137

0

Yates

64

0

 

Yesterday, there were 9 deaths due to COVID-19 in New York State, bringing the total to 25,479. A geographic breakdown is as follows, by county of residence:

 

Deaths by County of Residence

County

New Deaths

Allegany

2

Chemung

1

Essex

1

Kings

2

Queens

2

Suffolk

1





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

Are Organ Transplant Recipients at Greater Risk of Death from COVID-19? - Michigan Medicine

10/1/2020

0 Comments

 
Are Organ Transplant Recipients at Greater Risk of Death from COVID-19? - Michigan Medicine

https://ift.tt/3n8hDxd

A new study, published in Transplantation, finds that risk of death from COVID-19 in organ transplant recipients may be based upon how the patient was treated.

“Using data from the COVID-19 Rapid Response Registry, we examined COVID-19 positive adult solid organ transplant recipients and non-transplant patients that were matched to them on age, race and whether they were admitted at the hospital or seen at an outpatient facility,” says lead author of the study, Pratima Sharma, M.D., an associate professor of medicine and a transplant hepatologist at Michigan Medicine.

Sharma says the demographics of patients included in the study were also consistent with COVID-19 patient trends throughout the state of Michigan.

SEE ALSO: Seeking Medical Care During COVID-19

“Black Michiganders represent 15% of the total population in the state and account for 42% of COVID-19-related deaths, compared to white Michiganders who represent 75% of the population in the state and 26% of deaths from COVID-19,” she says.

“These statistics are also valid for solid organ transplant recipients, and while Black patients account for one tenth of all organ transplant recipients in our University of Michigan Transplant Center, they represented two-thirds of the COVID-19 positive organ transplant recipients group in this study,” she adds. “These results highlight the racial inequities that have overwhelmed the United States health care system during this pandemic.”

The research team found that disease severity and intubation rates were similar among both solid organ transplant recipients and non-transplant patients, but organ transplant recipients needed more renal replacement therapy, which takes over functioning for the kidneys when they are failing.

SEE ALSO: Keeping Our Patients Safe During COVID-19

While death due to severity of the virus was similar in both groups, the use of hydroxychloroquine treatment was associated with higher death rates among the organ transplant recipients.

“In fact, we found that the treatment of hydroxychloroquine among organ transplant recipients was associated with ten-fold higher risk of death compared to not using the treatment among the recipients,” Sharma says.

MORE FROM THE LAB: Subscribe to our weekly newsletter

Sharma and her colleagues hope that these findings encourage further scrutiny of hydroxychloroquine use in organ transplant recipients infected with COVID-19.

The study research team led by Sharma includes Michigan Medicine researchers from five divisions/units: Vincent Chen, M.D., Vaiibhav Patel, M.D., Michael Combs, M.D., Silas Norman, M.D., Puneet Garg, M.D., Monica Colvin, M.D., Jonathan Golob, M.D., Ph.D., and Monica Doshi, M.D., of the Department of Internal Medicine; Christopher Sonnenday, M.D., MHS, of the Department of Surgery; Christopher Fung, M.D., of the Department of Emergency Medicine; Emily Somers, Ph.D., of the U-M School of Public Health; and Jonathan Troost, Ph.D., of the Michigan Institute for Clinical and Health Research.

Paper cited: “COVID-19 Outcomes Among Solid Organ Transplant Recipients,” Transplantation. DOI: 10.1097/TP.0000000000003447





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

Guterres urges more countries to step up and fund global COVID-19 vaccine effort - UN News

10/1/2020

0 Comments

 
Guterres urges more countries to step up and fund global COVID-19 vaccine effort - UN News

https://ift.tt/2HGnYQh

The Access to COVID-19 Tools – the ACT-Accelerator – along with its COVAX Facility, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines. 

Launched at the end of April 2020, the ACT-Accelerator has secured $3 billion, critical for its start up, but it needs a further $35 billion – including an “immediate infusion” of $15 billion – Secretary-General António Guterres said at a high-level event to mobilize support for the initiative. 

“These resources are crucial now to avoid losing the window of opportunity for advance purchase and production, to build stocks in parallel with licensing, to boost research, and to help countries prepare to optimize the new vaccines when they arrive.”  

Any delay would further widen already vast inequalities, he warned. 

‘By helping others, countries help themselves’ 

Mr. Guterres outlined clearly that to reach that amount, donors’ paying in through official development assistance budgets, will not be sufficient. 

It is time for countries to draw funding from their own response and recovery programmes. By helping others, they will help themselves – Secretary-General Guterres

“We need to think bigger. It is time for countries to draw funding from their own response and recovery programmes. By helping others, they will help themselves”, he said. 

The coronavirus pandemic is costing the global economy $375 billion a month and has destroyed around 500 million jobs so far. 

The Secretary-General called on developed countries – which have devoted many trillions of dollars to respond to the socio-economic impacts of the crisis in their own countries – to “invest a small fraction of that, to stop the spread of the disease everywhere.” 

“I call on all countries and partners to significantly step up in the next three months to provide much needed new and additional resources and to mobilize all partners and to put everyone behind a global response to deliver. Solidarity is self-interest,” he stressed. 

“Grasping that 21st-century truth is essential to end this crisis and emerge safer, smarter and stronger together,” he said, wrapping up his remarks. 

‘A test of solidarity’ 

Amid the devastation of COVID-19, science is offering solutions, in the form of new tests, therapeutics and – hopefully – vaccines, said Tedros Adhanom Ghebreyesus, Director-General of the UN World Health Organization (WHO), speaking alongside the Secretary-General. 

Science and solutions are, however, ineffective without solidarity, he added. 

The head of WHO explained that the ACT-Accelerator has already delivered “impressive results” in the form of making available 120 million new rapid tests for low- and middle-income countries and securing courses of dexamethasone. 

The financing gap for ACT-Accelerator stands at $35 billion … roughly equivalent to what the world spends on cigarettes every two weeks – WHO DG Tedros 

The COVAX facility, on its part, is supporting the development of vaccines, he continued, underlining that “now is the time to realize the full power of ACT-Accelerator.”  

With the $35 billion financing gap – roughly equivalent to what the world spends on cigarettes every two weeks - the WHO Director-General said that fully funded, the initiative will help control the pandemic, restore confidence and stimulate the growth of the recovery. 

“Frankly, this is not a financial challenge, it is a test of solidarity. This is a moment to say no to nationalism, and yes to our shared humanity,” he declared, adding “ultimately ACT is not delivering merely vaccines, diagnostics or therapeutics, it is delivering something far more important – hope.”  

Eliminate COVID-19 everywhere 

Philanthropist and Microsoft co-founder Bill Gates, also addressing the summit, said that a vaccine against COVID-19 will help save millions of lives as well as support the development of a plan to eliminate the disease globally.  

To achieve global elimination, he outlined three necessities: capacity to produce billions of vaccines, funding to pay for them, and systems to deliver them everywhere. 

“A vaccine can make COVID-19 a preventable disease, and no one should die from a preventable disease simply because the country they live in can’t afford the vaccine,” he added, urging action to ensure low- and lower-middle income countries can also access sufficient doses to protect their populations.    

“The only way to eliminate the threat of this disease somewhere, is to eliminate it everywhere,” said Mr. Gates.  

UN Web TV | Broadcast of the high-level event

New agreement with pharma 

Mr. Gates announced that the Bill and Melinda Gates Foundation, earlier on Wednesday, had signed a new agreement with 16 pharmaceutical companies. 

“In this agreement the companies commit to, among other things, scaling up manufacturing at an unprecedented speed, and making sure that approved vaccines reach broad destruction as early as possible”, he said. 

The next necessity to eliminate COVID-19, is the funding to pay for those vaccines.  

Mr. Gates said that the pharmaceutical industry has committed to make the products as affordable as possible, through donations, tiered pricing and foregoing profits, and underlined the need for public funding, to procure vaccines for all. 

“This is where the ACT-Accelerator comes in,” said Mr. Gates, applauding the United Kingdom for donating enough money to purchase hundreds of millions of doses of vaccines for poor countries. “I want to encourage other countries to do the same”, he said. 

“Finally even when we have the manufacturing capacity and the funding lined up, we will need to strengthen health systems to achieve the broad coverage to deliver the vaccine, and monitor for outbreaks”, he said, adding that lessons learnt from polio eradication efforts can be used for that purpose. 

With the right diagnostics, health workers can also sound the alarm if a future disease jumps from animal to humans, said Mr. Gates, adding: “In other words, we can also be building the systems that will help reduce the damage of the next pandemic.”





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

UW researchers driving around Seattle to track COVID-19 response over time - UW News

10/1/2020

0 Comments

 
UW researchers driving around Seattle to track COVID-19 response over time - UW News

https://ift.tt/34g5E8x

Engineering  |  Public Health  |  Research  |  Science  |  Technology  |  UW News blog

September 30, 2020

UW researchers driving around Seattle to track COVID-19 response over time

A panoramic view of a street corner. Cars and a pedestrian are labeled

UW researchers developed a project that scans the streets every few weeks to document how Seattle has reacted to the pandemic and what recovery looks like. The team is developing algorithms to help identify things such as cars, people and whether they are physically distancing in each frame.University of Washington

As the city of Seattle shut down in March 2020 to try to slow the spread of COVID-19, a group of University of Washington researchers got to work.

The team developed a project that scans the streets every few weeks to document what’s happening around the city — answering questions such as: Are people outside? Are restaurants open? This project, which began in May and will continue until at least fall of 2021, collects images of how Seattle has reacted to the pandemic and what recovery looks like. This creates a massive dataset that documents what was happening at any particular point in time. The researchers hope the data will help answer questions about what makes a city resilient and how to better prepare for potential future pandemics and other disasters.

The team will present this project Oct. 1 at the Environmental and Occupational Health webinar through the UW School of Public Health.

“We talk about resilience a lot in disaster sciences. There are lots of theories about what makes a community resilient to natural hazards, but we don’t fully understand resilience to pandemics, partially because we just haven’t been through these events at this scale,” said co-lead researcher Nicole Errett, an assistant professor of environmental and occupational health sciences. “This project provided us with an opportunity to see what’s important for resilience in this context. What are people doing? Where are they recreating? Are they following distancing and mask-wearing recommendations? And how do their activities change as the pandemic progresses?”

Video footage taken from the team’s first drive on May 1, 2020.

To track what’s happening in Seattle, the researchers drive a car with a camera similar to Google Street View on top throughout the city.

“This is an amazing tool for quickly gathering highly perishable data from across the city,” said co-lead researcher Joseph Wartman, a professor of civil and environmental engineering. “Unless we capture these scenes now, these sights — and the rich data they contain — will be lost forever. I can already see a significant difference between the May dataset and what’s happening now. For example, when we first drove past Harborview Medical Center, no one was present on the block. Now it’s beginning to look like it used to.”

The team captured this series of photos from outside Harborview Medical Center between June and August 2020. The June photo shows very few people in the area. In July, there are people waiting at the bus stop. By August, there are more people at the bus stop and the surrounding areas. Credit: University of Washington

The team’s route takes between eight and 11 hours to drive each time.

“We wanted the route to capture different aspects of the city — such as restaurants, hospitals, schools, parks and museums — and also make sure we had an equal representation across a variety of neighborhoods,” said co-lead researcher Scott Miles, a senior principal research scientist in the human centered design and engineering department.

The researchers try to start the drive at 8 a.m. on Friday, every few weeks, to maintain a consistent schedule, but it depends on weather, specifically the camera doesn’t work in the rain. They also drive on some Sundays to try to capture any variation between weekdays and weekends.

The Street-View-like camera creates huge datasets — each drive is turned into tens of thousands of images that make up an almost 2-terabyte file. So the researchers are developing algorithms to help them identify things such as cars, people and whether they are physically distancing in each frame. Identities — such as human faces and vehicle license plates — will be blurred.

“When people study disaster recovery, they often look at location data from smartphones or transaction data from debit or credit cards,” said co-lead researcher Youngjun Choe, an assistant professor of industrial and systems engineering. “But these data points do not necessarily capture everyone in a community. By looking at our images, I hope we are creating a dataset that better represents all people who live and work in Seattle.”

Any insights gained from this project, such as how people respond to mask recommendations or which populations might need more resources, can help other cities better understand their own recovery trends the researchers said.

“People talk about this as a 100-year pandemic, because the last major pandemic was in 1918,” Errett said. “Now conditions are much different — we have increased population density, climate change and more. I don’t think we’re going to be waiting another hundred years. So whatever we can do to learn from this experience will help us develop better policies and plans for the future.”

Jaqueline Peltier, an operations specialist in civil and environmental engineering; Matthew Martell, a doctoral student in industrial and systems engineering; Christopher Salazar, a master’s student in industrial and systems engineering; and Vanessa Yang, an undergraduate student in statistics and informatics, are also part of this project. This research is funded by the National Science Foundation.

For more information, contact Errett at nerrett@uw.edu, Wartman at wartman@uw.edu, Miles at milessb@uw.edu and Choe at ychoe@uw.edu.

Grant number:  CMMI-2031119

Tag(s): College of Engineering • COVID-19 • COVID-19 studies • Department of Civil & Environmental Engineering • Department of Environmental & Occupational Health Sciences • Department of Human Centered Design & Engineering • Department of Industrial & Systems Engineering • Joseph Wartman • Nicole Errett • School of Public Health • Scott Miles • Youngjun Choe




Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

Elon Musk doubles down on Covid-19 skepticism and says he wont take future vaccine - The Mercury News

10/1/2020

0 Comments

 
Elon Musk doubles down on Covid-19 skepticism and says he won’t take future vaccine - The Mercury News

https://ift.tt/2Gu72vG

By Ganesh Setty | CNN Business

Elon Musk is once again publicly downplaying the risks of Covid-19.

In a wide-ranging interview with the journalist Kara Swisher, the Tesla and SpaceX CEO said he would not take a Covid-19 vaccine when one becomes available, and declined to say whether he feels a duty to pay employees who want to stay home to avoid contracting the virus.

“I’m not at risk for Covid, nor are my kids,” said Musk during Monday’s episode of the New York Times podcast “Sway.”

Musk has long cultivated a public persona of an eccentric entrepreneur who knows better than the experts and isn’t afraid to offer controversial opinions.

On the podcast, Musk argued that instead of sweeping stay-at-home orders to mitigate the spread of coronavirus, “anyone who is at risk should be quarantined until the storm passes.”

When Swisher confronted Musk with the possibility that people would still die in the process, he replied bluntly: “Everybody dies.”

“The question is what, on balance, serves the greater good,” Musk continued, adding that the lockdowns did not accomplish that and the pandemic is a “no-win situation.”

Musk, the third-richest person in the world according to the Bloomberg Billionaires Index, tweeted in April that nationwide stay-at-home orders amounted to “de facto house arrest.”

If one of his workers told him that coming to work would put their family at risk, Musk said he would simply tell them to “stay home.”

He declined to elaborate on whether he would feel obliged to pay them. When Swisher pressed, Musk grew defensive, threatening to end the interview. “Let’s just move on…Kara, I do not want to get into a debate about Covid, this situation … If you want to end the podcast now, we can do it.”

Musk also took aim at fellow billionaire Bill Gates, who in late July told journalist Andrew Ross Sorkin that Musk ought to stick to what he knows best.

“Elon’s positioning is to maintain a high level of outrageous comments,” Gates said. “He’s not much involved in vaccines. He makes a great electric car. And his rockets work well. So he’s allowed to say these things. I hope that he doesn’t confuse areas he’s not involved in too much.”

Musk responded on the podcast in his typically blunt manner: “It’s like, hey, knucklehead, we actually make the vaccine machines for CureVac, that company you’re invested in.”

It’s not the first time Musk has criticized the Microsoft co-founder.

When Gates blogged his doubts earlier this month on the potential for long-haul electric vehicles, Musk tweeted that Gates “has no clue.”

The-CNN-Wire
™ & © 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.





Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study - The Lancet

10/1/2020

0 Comments

 
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study - The Lancet

https://ift.tt/3ijtB3N

Fever (>38·0°C) Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
8
  • Fardet L
  • Galicier L
  • Lambotte O
  • et al.

Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.

, 
10
  • Henter JI
  • Horne A
  • Aricó M
  • et al.

HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

, 
11
  • Davì S
  • Consolaro A
  • Guseinova D
  • et al.

An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.

, 
14
  • Parodi A
  • Davì S
  • Pringe AB
  • et al.

Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients.

, 
15
  • Ravelli A
  • Minoia F
  • Davì S
  • et al.

2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

, 
33
  • Shimazaki C
  • Inaba T
  • Nakagawa M

B-cell lymphoma-associated hemophagocytic syndrome.

, 
44
  • Chen N
  • Zhou M
  • Dong X
  • et al.

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
46
  • Wang D
  • Hu B
  • Hu C
  • Zhu F
  • Liu X
  • Zhang J

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.

, 
47
  • Xu XW
  • Wu XX
  • Jiang XG
  • et al.

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.

>90% have fever
Hepatosplenomegaly Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

ND Unknown
Encephalopathy Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

48
  • Espinosa PS
  • Rizvi Z
  • Sharma P
  • Hindi F
  • Filatov A

Neurological complications of coronavirus disease (COVID-19): encephalopathy, MRI brain and cerebrospinal fluid findings: case 2.

, 
49
  • Kishfy L
  • Casasola M
  • Banankhah P
  • et al.

Posterior reversible encephalopathy syndrome (PRES) as a neurological association in severe Covid-19.

, 
50
  • Hayashi M
  • Sahashi Y
  • Baba Y
  • Okura H
  • Shimohata T

COVID-19-associated mild encephalitis/encephalopathy with a reversible splenial lesion.

, 
51
  • Zayet S
  • Ben Abdallah Y
  • Royer PY
  • Toko-Tchiundzie L
  • Gendrin V
  • Klopfenstein T

Encephalopathy in patients with COVID-19: ‘causality or coincidence?’.

, 
52
  • Filatov A
  • Sharma P
  • Hindi F
  • Espinosa PS

Neurological complications of coronavirus disease (COVID-19): encephalopathy.

Observed but incidence unknown
Haemoglobin, g/dL Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Moderate to low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Mildly low to normal
1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

12·2 vs 13·4
Platelets, 109 cells per L Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Mildly low to normal Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Mildly low to normal
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
56
  • Deng Y
  • Liu W
  • Liu K
  • et al.

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.

, 
57

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

143–187 vs 173–222
White blood count, 109 cells per L Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Mildly low to normal Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Mildly low to normal
1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
59
  • Richardson S
  • Hirsch JS
  • Narasimhan M
  • et al.

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.

3·3–11·0 vs 4·7–5·3
Absolute lymphocyte count, 109 cells per L Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Mildly low to normal Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
56
  • Deng Y
  • Liu W
  • Liu K
  • et al.

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.

, 
57

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

, 
60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

0·5–0·8 vs 1·0–1·4
Neutrophil to lymphocyte ratio Mildly low to normal Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

ND Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
57

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

, 
60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

, 
61
  • Wang Y
  • Ju M
  • Chen C
  • et al.

Neutrophil-to-lymphocyte ratio as a prognostic marker in acute respiratory distress syndrome patients: a retrospective study.

5·5–22·0 vs 2·8–4·4
Ferritin, ng/mL Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
57

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

, 
60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

, 
62

Clinical and immunological features of severe and moderate coronavirus disease 2019.

800–1598 vs 337–523
Lactate dehydrogenase, U/L Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

, 
60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

, 
62

Clinical and immunological features of severe and moderate coronavirus disease 2019.

, 
63
  • Mo P
  • Xing Y
  • Xiao Y
  • et al.

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.

400–905 vs 221–297
D-dimer, μg/mL Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
56
  • Deng Y
  • Liu W
  • Liu K
  • et al.

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.

, 
60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

, 
62

Clinical and immunological features of severe and moderate coronavirus disease 2019.

, 
64
  • Zhang L
  • Yan X
  • Fan Q
  • Liu H
  • Liu X
  • Liu Z

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.

, 
65
  • Thachil J
  • Tang N
  • Gando S
  • et al.

ISTH interim guidance on recognition and management of coagulopathy in COVID-19.

, 
66
  • Goshua G
  • Pine AB
  • Meizlish ML
  • et al.

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.

0·6–4·0 vs 0·3–0·5
Triglycerides, mg/dL Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Mildly low to normal Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

180 vs 120
Fibrinogen, mg/dL Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Moderate to low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Extremely low
‡

‡ Indicates magnitude of decrease below the lower limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
66
  • Goshua G
  • Pine AB
  • Meizlish ML
  • et al.

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.

630 vs 450
Aspartate aminotransferase, U/L Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

1
  • Guan WJ
  • Ni ZY
  • Hu Y
  • et al.

Clinical characteristics of coronavirus disease 2019 in China.

, 
45
  • Huang C
  • Wang Y
  • Li X
  • et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

, 
53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
56
  • Deng Y
  • Liu W
  • Liu K
  • et al.

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

, 
62

Clinical and immunological features of severe and moderate coronavirus disease 2019.

, 
63
  • Mo P
  • Xing Y
  • Xiao Y
  • et al.

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.

38–288 vs 24–40
Interleukin-6, pg/mL Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
55

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

, 
57

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

, 
60
  • Jordan RE
  • Adab P
  • Cheng KK

Covid-19: risk factors for severe disease and death.

, 
63
  • Mo P
  • Xing Y
  • Xiao Y
  • et al.

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China.

, 
67
  • Chen X
  • Zhao B
  • Qu Y
  • et al.

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.

6–72 vs 6–13
Soluble interleukin-2 receptor-α (also known as sCD25), pg/mL Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Mildly low to normal
57

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

, 
68
  • Hou H
  • Zhang B
  • Huang H
  • et al.

Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.

757 vs 663
C-reactive protein
§

§ Not high-sensitivity C-reactive protein.

, mg/L
Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Moderate to high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

Extremely high
†

† Indicates magnitude of increase above the upper limit of normal.

53

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

, 
54

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

, 
56
  • Deng Y
  • Liu W
  • Liu K
  • et al.

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study.

, 
58
  • Ruan Q
  • Yang K
  • Wang W
  • Jiang L
  • Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

, 
69
  • Liu K
  • Fang YY
  • Deng Y
  • et al.

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province.

34–126 vs 8–23




Health

via COVID-19 https://ift.tt/2RRN1ld

October 1, 2020 at 01:03AM
0 Comments

All the Things Hyaluronic Acid Can Do for Your Skin Bones and Beyond

9/30/2020

0 Comments

 
All the Things Hyaluronic Acid Can Do for Your Skin, Bones, and Beyond

https://ift.tt/3cS1RSz

OK, now that you know what it does, how do you go about using it?

Hyaluronic acid is available in multiple forms, including oral supplements, applied serums, and injectables. Which one you choose ultimately comes down to what you’re using it for, what your budget is, and personal preference.

Oral hyaluronic acid. It’s always best to speak with a trusted health professional before using an oral supplement. Studies have shown that taking 120 to 240 milligrams per day for at least a month significantly reduced dry skin and increased moisture.

Topical hyaluronic acid. Along with hyaluronic acid serums, there are creams and makeup that feature the acid as a main ingredient. As with any new skin care ingredient, results and side effects may vary. However, because hyaluronic acid is naturally occurring, side effects are usually limited.

Injectable hyaluronic acid. Some dermatologists offer injectable hyaluronic acid fillers, and while the treatment is considered safe, this guide will focus on options that are readily available for purchase by consumers for at-home use, namely oral and topical.

For any of the non-skin-related uses above, you should talk with a doctor or seek advice at a local health clinic to talk about whether HA is right for you — and if so, what form, dose, and frequency, etc.

As for beauty applications, we’ve got you covered. If you’re ready to try out hyaluronic acid for acne, dry skin, pesky wrinkles, or just some glowy skin, we’ve gathered the best products to try out. Looking to ease a dry scalp or encourage the growth of luscious locks? We’ve got that on the list too.

We chose these products based on their effective ingredients and rave reviews from customers. We’ve included options that are serums and supplements, as well as beauty products that include hyaluronic acid.

While they range in price, most of the products on this list are less than $40.

Pricing guide

$ = under $10
$$ = $10–$35
$$$ = over $60

This $7 serum combines hyaluronic acid and vitamin B5 to provide dry skin with much-needed moisture. Suggested for use twice a day, the liquid-based product left the faces of someone online reviewers looking more luminous than ever, and some reported softer skin.

Key ingredients: hyaluronic acid, sodium hyaluronate crosspolymer, vitamin B5 (as panthenol)

Price: $

Buy The Ordinary Hyaluronic Acid online.

Those interested in incorporating hyaluronic acid through a daily cleansing routine should consider this face wash. The cream-based cleanser washes away makeup and dirt, but it’s blend of hyaluronic acid, Japanese algae, and Japanese rice powder should also leave skin feeling softer.

Key ingredients: hyaluronic acid, blend of nourishing Japanese algae and Japanese rice powder

Price: $$

Buy Tatcha The Rice Wash Skin-Softening Cleanser online.

By adding hyaluronic acid directly into this tinted moisturizer, users can skip the added step of doubling up on separate products. Plus, as moisturizer is proven effective in treating oily skin, you’re getting both the benefits of the hyaluronic acid, and the added moisture.

The product is available in multiple tinted shades, but you should be wary of application, as some reported it looking “streaky and patchy,” while others experienced breakouts.

Key ingredients: hyaluronic acid, coconut water (cocos nucifera water)

Price: $$

Buy ColourPop Pretty Fresh Hyaluronic Acid Tinted Moisturizer online.

More than 1,000 shoppers have given this moisturizer a five-star seal of approval, citing its combination of hyaluronic acid and rose water as the reason for “dewy” skin. Sensitive skin users praised the product, but those with oily skin cited additional breakouts possibly related to use.

Key ingredients: hyaluronic acid, angelica keiskei extract, rose water as rosa damascena flower oil, tocopheryl acetate

Price: $$

Buy Fresh Rose & Hyaluronic Acid Deep Hydration Moisturizer online.

Peptides focused on reducing wrinkles and fine lines join hyaluronic acid in this popular serum. The serum’s $8 price is partially responsible for its popularity, with consumers calling it a “cost-effective” alternative to similar, more expensive products.

“This feels amazing on the skin,” one reviewer wrote, while another said it doesn’t feel sticky when applied.

Key ingredients: hyaluronic acid, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1

Price: $

Buy The INKEY List Hyaluronic Acid Hydrating Serum online.

Thanks to the quick-absorbing formula of this gel, this is one product that can easily be worn under liquid makeup.

Suitable for all skin types, some online reviewers swear by the item, writing, “My cystic acne has ceased, my skin is supple, clear, brightened.” Another reviewer dubbed it an “effective, affordable” alternative to more expensive products.

For those with a sensitive nose, some customers did note that they were not a fan of the product’s fragrance.

Key ingredients: hyaluronic acid

Price: $$

Buy Neutrogena Hydro Boost online.

This balm allows your lips to take advantage of the hydrating properties of hyaluronic acid. Formulated with shea butter and wild mint, the balm — which comes in three color variations — earned top marks from shoppers for leaving lips feeling “lush” and its lightweight application.

Not everyone is a fan of the balm’s packaging though, as some reported issues with the balm’s thin applicator.

Key ingredients: hyaluronic acid, shea butter, avocado oil

Price: $$

Buy Kosas Kosasport LipFuel Hyaluronic Lip Balm online.

Hypoallergenic and tested by dermatologists, this intensive cream provides long-lasting hydration to the face.

Customers reported that a little goes a long way with usage, and some noticed instant results. However, some did report that it doesn’t mix well with makeup, and that on some occasions, it didn’t feel truly absorbed by the skin.

Key ingredients: hyaluronic acid, sunflower seed oil

Price: $$

Buy CORSX Hyaluronic Acid Intensive Cream online.

The addition of vitamin B5 and algae extract enables this hyaluronic acid serum to also target fine lines and wrinkles. Although the formula did feel “sticky” to some users, others suggested applying moisturizer after to counteract that.

Key ingredients: hyaluronic acid, vitamin B5, algae extract

Price: $$

Buy Tarte SEA Mermaid Skin Hyaluronic Acid Serum.

Not for the budget bound, this scalp serum is pricey. The serum provides a heavy dose of hydration and moisture to the scalp thanks to HA, purslane, and papaya extract. Caffeine energizes and panthenol soothes. It’s free of parabens, formaldehydes, phthalates, and more undesirables.

Key ingredients: hyaluronic acid, purslane, papaya extract, panthenol, caffeine

Price: $$$

Buy Dr. Barbara Sturm Scalp Serum.

Hyaluronic acid in supplement form can reduce dry skin, and this combination, which also features collagen, will also support overall skin health.

Online reviewers did report more “luminous” “hydrated” skin, but some were not a fan of the product’s texture, and others did not notice an improvement in their skin.

Key ingredients: hyaluronic acid, collagen, sea buckthorn

Price: $$

Buy Olly Glowing Skin Vitamin Gummies online.

Containing only hyaluronic acid as its key ingredient, this supplement, when taken as directed, delivers 200 milligrams of the beneficial skin care ingredient. One reviewer noted a lessening of wrinkles, but combined the supplement with additional moisturizers.

Key ingredients: hyaluronic acid

Price: $$

Buy NeoCell Hyaluronic Acid Capsules.





Health

via Greatist Health RSS Feed https://ift.tt/3gGiiSS

September 30, 2020 at 07:40PM
0 Comments
<<Previous
Forward>>

    Archives

    November 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017

    Categories

    All

    RSS Feed

(C) FeallHealthy2day.com 2017 - 2018
Some photos and content used under Creative Commons
  • Home
  • Recipes
  • Health News
  • Fitness News
  • Weight Loss
  • Contact
  • Subscribe